 Prime Medicine Inc, a biotechnology company specializing in gene editing, debuted on the Nasdaq Thursday after pricing one of the years largest IPOs in the sector. The Cambridge, Massachusetts-based company priced an upsized 10,294,118 shares of common stock at a public price of 17 each, good for expected gross proceeds of 175 million. 